NCT07034339 Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
| NCT ID | NCT07034339 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Condition | Immune Evasion, Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2025-05-21 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2025-05-21 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. This project aims to establish a large, multi-center pancreatic cancer cohort and a standardized clinical sample repository, capturing multimodal immunity big data on pancreatic cancer occurrence, progression, and treatment response across the spatial dimension of "peripheral versus local" and the temporal dimension of "tumor evolution/pre- and post-treatment." By integrating patient imaging and clinical information, the investigators will develop a technical platform for intelligent extraction and fusion analysis of cross-scale, multimodal data, thereby mapping the immunity landscape of pancreatic cancer evolution, identifying characteristic changes in immunity parameters, and devising an AI model for early pancreatic cancer diagnosis with high accuracy and robust generalization capabilities, while also exploring the model's interpretability. Additionally, the investigators will focus on specific immune cell subsets associated with pancreatic cancer evolution and treatment response, elucidating their roles and mechanisms in the occurrence, development, and drug resistance of pancreatic cancer. This project will establish a high-quality, standardized, and shareable pancreatic cancer immunity sample and data repository, refine the framework for multi-dimensional immunity data fusion and analysis, and create a time-space atlas of local and systemic immunity in pancreatic cancer. This will facilitate a deeper understanding of the dynamics of systemic and local immunity in early-stage pancreatic cancer and at various stages of its evolution, offering novel insights and approaches for the diagnosis and treatment of pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: * Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases * Primary PDAC * Patients with benign pancreatic tumors * IPMN patients diagnosed by pathology/imaging Exclusion Criteria: * Having autoimmune diseases * Accompanied by other malignant tumors * History of tumor treatment (except thyroid cancer and breast cancer, cured for more than 5 years) * Acute infection * History of blood transfusion within the past 6 months, or use of drugs that affect peripheral blood components such as recombinant human erythropoietin and interleukin within 2 weeks * Organ decompensation dysfunction * Immunodeficiency syndrome * Hematological precancerous lesions * Accept immunosuppressive therapy * Diagnosed coagulation disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07034339 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Immune Evasion, Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07034339 currently recruiting?
Yes, NCT07034339 is actively recruiting participants. Contact the research team at 12418635@zju.edu.cn for enrollment information.
Where is the NCT07034339 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07034339 clinical trial?
NCT07034339 is sponsored by First Affiliated Hospital of Zhejiang University. The trial plans to enroll 1,500 participants.